Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF) has announced the successful closing of a private placement of 17,445,455 units at a price of $0.55 per unit, generating gross proceeds of approximately $9.6 million. Each unit consists of one common share and one common share purchase warrant, with the warrants exercisable at $0.65 for a period of 24 months. This financing comes on the heels of a previously disclosed term sheet with institutional investors, which had initially outlined a commitment of $6 million. The company intends to allocate the funds towards advancing its Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs, as well as for working capital purposes.
Historically, Defence Therapeutics has positioned itself as a biotechnology firm focused on enhancing cancer treatment efficacy through its Accum® precision drug delivery platform. The successful closure of this financing is crucial for the company, particularly as it seeks to develop partnerships and further its research initiatives. The timing of this announcement, just days after the execution of the term sheet on March 6, 2026, suggests a swift execution of its funding strategy, which is often a positive signal in the biotech sector where capital is essential for R&D activities.
As of the latest available data, Defence Therapeutics has a market capitalisation of approximately $40 million. The company’s cash balance post-financing will be around $12 million, assuming no significant expenditures occur before the next reporting period. This financial position provides a reasonable runway for ongoing projects, particularly when considering the average burn rate for biotech companies in the development stage, which can vary widely but often ranges from $1 million to $3 million per quarter. Given this context, Defence Therapeutics appears to have a funding runway of approximately 4 to 12 months, depending on the pace of its operational expenditures.
In terms of valuation, Defence Therapeutics is currently trading at an enterprise value of approximately $36 million, factoring in the new cash influx from the private placement. This valuation can be compared to direct peers such as Oncolytics Biotech Inc. (NASDAQ: ONCY), which has an enterprise value of around $100 million and focuses on similar oncology therapeutics. Another comparable company is Zymeworks Inc. (NYSE: ZYME), with an enterprise value of approximately $200 million, also in the oncology space. On a per-share basis, Defence Therapeutics’ valuation metrics such as EV per share are significantly lower than its peers, indicating potential undervaluation if the company can successfully execute its development plans.
The execution record of Defence Therapeutics has been mixed, with the company having previously set ambitious timelines for its ADC and Radiopharmaceutical programs. However, the recent announcement of the private placement aligns with prior guidance indicating a need for additional capital to meet developmental milestones. The management team has historically faced challenges in meeting projected timelines, which raises concerns about the potential for further delays in project advancement. Additionally, the issuance of warrants, which could lead to dilution if exercised, poses a risk to existing shareholders, particularly if the share price does not appreciate significantly above the exercise price of $0.65.
A specific risk highlighted by this announcement is the reliance on successful partnerships to leverage the newly raised capital effectively. The biotechnology sector is notoriously competitive, and the ability to secure collaborations with larger pharmaceutical companies is critical for advancing product development. Failure to establish such partnerships could hinder the company’s growth trajectory and impact its long-term viability.
Looking ahead, the next measurable catalyst for Defence Therapeutics is expected to be the announcement of strategic partnerships or collaborations, which the company has indicated it is actively pursuing. This is anticipated to occur within the next three to six months, as the company seeks to leverage its recent funding to attract larger players in the biotech space.
In conclusion, the announcement of the private placement is classified as significant. It materially enhances Defence Therapeutics’ financial position, providing necessary capital to advance its ADC and Radiopharmaceutical programs. However, the execution risks and potential dilution from the warrants issued must be carefully monitored. The company’s ability to attract partnerships will be crucial in determining its future valuation and operational success.